Earnings Call Intelligence Subscribe
Home › Call Sheets › PFE › Q4'25
Call sheet · Q4'25

Pfizer (PFE)

Q4'25 earnings call · held February 3, 2026 · compared with the Q3'25 call · management-credibility review
9/12
Disclosure score
1 high, 3 medium, 2 low flags
Financial quality
Bottom line
The sleeper story is AI driving real productivity gains right now - not just future promise, but the 'main lever' behind $600M+ savings and accelerating R&D output. While the market will focus on Metsera's monthly GLP-1 data, the 16% weight loss projection is model-based, not proven efficacy. The binding constraint isn't obesity competition but regulatory alignment uncertainty - PCV-25 timeline slip shows FDA pushback emerging. Bourla's most revealing quote: 'Many people are asking us how Pfizer was able to take so much cost out...the main lever was successful deployment of AI.' My view changes if the VESPA-6 Phase 3 design differs materially from the model assumptions, or if more regulatory timelines slip beyond PCV-25.

The 30-second version

  • SLEEPER STORY: AI is the real cost story, not just obesity dealmaking
  • Metsera monthly GLP-1 data validates differentiation, but watch the modeling
  • COVID revenue floor is real - lowest ever season generated $1.3B, guidance assumes ~$5B for 2026

What changed this quarter

MetricQ3'25Q4'25Change
Total Revenue$16.7B (-7% YoY operational)$17.6B (-3% YoY operational)Acceleration despite COVID headwinds
Non-COVID Revenue4% operational growth9% operational growth+500 bps acceleration in core business
Adjusted Gross Margin76%71%-500 bps compression on product mix
Adjusted EPS$0.87 (ahead of expectations)$0.66 (ahead of expectations)Maintained beat despite lower margins
COVID-19 ProductsDecline from reduced demand~40% operational decline YoYAccelerated decline to lowest ever
Recently Launched/Acquired Products$7.3B (9% operational growth YTD)$10.2B (14% operational growth FY)+500 bps acceleration for full year
Vyndaqel Family7% YoY operational growthSolid performanceMaintaining growth despite new competition
Nurtec ODT22% YoY operational growthStrong market leadership83% of new CGRP writer volume captured
Manufacturing Optimization SavingsPhase 1 ongoing$600M through 2025Ahead of $1.5B target by 2027
R&D Investment$7.2B in 9 months$10.4B for full year43% increase in investment pace

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full PFE Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.